Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02307409
Other study ID # ILBS-SIRS-01
Secondary ID
Status Completed
Phase N/A
First received November 18, 2014
Last updated February 7, 2018
Start date June 1, 2014
Est. completion date August 1, 2016

Study information

Verified date April 2016
Source Institute of Liver and Biliary Sciences, India
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study attempts to clarify the pathophysiology of haemostasis and haematopoiesis in relation to the evidence of sepsis in liver disease, and compares the accuracy of various available laboratory tests in assessment of these patients. Further research is needed for proper understanding of the influence of sepsis on coagulation disorders in ACLF (Acute on Chronic Liver Failure) patients in particular, to correctly identify the type and optimal quantity of blood product requirement in at risk patients.

Thromboelastography (TEG) /Sonoclot have been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products. Secondly, the study of derangement in coagulopathy after the onset of sepsis is of paramount importance because of increased mortality after the onset of sepsis. In the present study, patients with ACLF (Acute on Chronic Liver Failure) without evidence of sepsis on admission will be included in the study cohort, and will undergo a baseline diagnostic workup as described. They will be followed for development of any signs of infection after hospitalization. Then the effect of sepsis on their coagulation and haematopoietic cellular responses will be assessed. Thus the effect of sepsis on the progression and outcome of patients with ACLF (Acute on Chronic Liver Failure) will be studied.


Recruitment information / eligibility

Status Completed
Enrollment 114
Est. completion date August 1, 2016
Est. primary completion date April 1, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age 18-65 years

- ACLF (Acute on Chronic Liver Failure), as diagnosed by APASL (Asian Pacific association of Study of Liver Disease) criteria mentioned above.

Exclusion Criteria:

- Patients with evidence of sepsis at presentation.

- Current therapy: Recent blood or blood component transfusion in the last 2 days.

- HIV positive/ AIDS patients

- Patients requiring anti platelet therapy,

- Renal insufficiency requiring dialysis

- Active malignancy within the last 5 years

- Patient with other neurological disease and metabolic disorders, unbalanced heart failure and/or respiratory failure or end-stage renal disease

- Administration of anticoagulants, antifibrinolytics,

- Not willing to participate in the study

- Pregnancy

Study Design


Intervention

Other:
Sonoclot/TEG test
The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis

Locations

Country Name City State
India Institute of Liver & Biliary Sciences New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
Institute of Liver and Biliary Sciences, India

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence and severity of coagulation profile derangement and haematopoietic responses, by sonoclot/ TEG, coagulation and hematological parameters, in acute- on-chronic liver failure with and without systemic inflammatory response. 0 day, 3 day & 7 day after admission.
Secondary Utility of sonoclot/ TEG in predicting blood product utilization. Reporting of blood product usage in 7 days of admission as per TEG R time, K time, Maximum amplitude of curve, angle, lysis at 30%. 0 day, 3 day & 7 day after admission.
Secondary Sonoclot/TEG result indicating hypocoagulability correlates with the patient's tendency to bleed in ACLF. Reporting of number and site of bleed- skin, mucosa, urine, GI tract, CNS etc. 0 day, 3 day & 7 day after admission.
Secondary Changes in baseline coagulation profile can predict development of sepsis in patients of ACLF. Correlation of PT/INR with TEG parameters and positive blood or urine culture. 0 day, 3 day & 7 day after admission.
Secondary Coagulation dysfunction (prothrombotic and anticoagulant tendencies) in patients with ACLF with or without evidence of sepsis. 0 day, 3 day & 7 day after admission.
Secondary Effect of sepsis on the haematopoietic response of patients with Acute on Chronic Liver Failure. Measurement of reticulocyte count, and peripheral amear- presence of toxic granules. 0 day, 3 day & 7 day after admission.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06069284 - Prognostic Significance of Acute Change in Liver and Splenic Stiffness in Patients of Acute on Chronic Liver Failure
Recruiting NCT03754400 - Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial). N/A
Not yet recruiting NCT06066814 - To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.
Completed NCT02573727 - To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure N/A
Completed NCT02583698 - Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices N/A
Not yet recruiting NCT06116305 - Lactate Kinetics as a Predictor of Survival in ACLF With Septic Shock
Completed NCT01074645 - Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure Phase 4
Recruiting NCT05124041 - Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy N/A
Not yet recruiting NCT06340269 - Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF N/A
Recruiting NCT01866072 - Evaluation of Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure N/A
Terminated NCT02788240 - To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase N/A
Not yet recruiting NCT05772585 - Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
Withdrawn NCT05131230 - CytoSorb® in Patients With Acute on Chronic Liver Failure
Completed NCT02467348 - Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure. N/A
Not yet recruiting NCT06276907 - An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response N/A
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Completed NCT03065699 - Safety and Performance Trial of DIALIVE Liver Dialysis Device in Acute On Chronic Liver Failure Patients N/A
Recruiting NCT02757170 - Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Phase 4
Recruiting NCT04054037 - A Study of AARC Standards on Diagnosis and Treatment of Patients With HBV-ACLF in China (AARC China Study)
Recruiting NCT05180292 - Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study. N/A